S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Challenge for Tunisian democracy: Getting voters to show up
FTX's Sam Bankman-Fried, DOJ tussle over his communications
The Next Big Crisis Is Here (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Qatar replaces Russian company in Lebanon gas exploration
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Challenge for Tunisian democracy: Getting voters to show up
FTX's Sam Bankman-Fried, DOJ tussle over his communications
The Next Big Crisis Is Here (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Qatar replaces Russian company in Lebanon gas exploration
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Challenge for Tunisian democracy: Getting voters to show up
FTX's Sam Bankman-Fried, DOJ tussle over his communications
The Next Big Crisis Is Here (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Qatar replaces Russian company in Lebanon gas exploration
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Challenge for Tunisian democracy: Getting voters to show up
FTX's Sam Bankman-Fried, DOJ tussle over his communications
The Next Big Crisis Is Here (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Qatar replaces Russian company in Lebanon gas exploration
NASDAQ:REGN

Regeneron Pharmaceuticals - REGN Stock Forecast, Price & News

$742.83
+0.53 (+0.07%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$740.27
$748.28
50-Day Range
$680.49
$766.39
52-Week Range
$538.01
$779.00
Volume
417,648 shs
Average Volume
552,514 shs
Market Capitalization
$80.89 billion
P/E Ratio
15.66
Dividend Yield
N/A
Price Target
$786.15

Regeneron Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.65 Rating Score
Upside/​Downside
5.8% Upside
$786.15 Price Target
Short Interest
Healthy
1.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.68
Upright™ Environmental Score
News Sentiment
0.49mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 21 Articles This Week
Insider Trading
Selling Shares
$14.07 M Sold Last Quarter
Proj. Earnings Growth
-3.69%
From $38.24 to $36.83 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

254th out of 1,054 stocks

Pharmaceutical Preparations Industry

123rd out of 517 stocks


REGN stock logo

About Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Stock News Headlines

Four Undervalued Healthcare Stocks for 2023 (REGN)
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Regeneron Pharma: CHMP Adopts Positive Opinion For Dupixent
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
12 Cheap Biotech Stocks To Buy
REGN Regeneron Pharmaceuticals, Inc.
Company News for Jan 10, 2023
See More Headlines
Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Company Calendar

Last Earnings
11/03/2022
Today
1/29/2023
Next Earnings (Confirmed)
2/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
Employees
10,368
Year Founded
1988

Price Target and Rating

Average Stock Price Forecast
$786.15
High Stock Price Forecast
$970.00
Low Stock Price Forecast
$625.00
Forecasted Upside/Downside
+5.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.65
Research Coverage
20 Analysts

Profitability

Net Income
$8.08 billion
Pretax Margin
44.04%

Debt

Sales & Book Value

Annual Sales
$16.07 billion
Cash Flow
$80.83 per share
Book Value
$172.92 per share

Miscellaneous

Free Float
99,112,000
Market Cap
$80.89 billion
Optionable
Optionable
Beta
0.22

Social Links


Key Executives

  • Leonard S. SchleiferLeonard S. Schleifer
    Co-President, Chief Executive Officer & Director
  • George Damis YancopoulosGeorge Damis Yancopoulos
    Co-President, Director & Chief Scientific Officer
  • Patrice Gilooly
    Senior VP-Quality Assurance & Operations
  • Robert E. LandryRobert E. Landry
    Chief Financial Officer & Executive VP-Finance
  • Neil StahlNeil Stahl
    Executive VP-Research & Development













REGN Stock - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REGN shares.
View REGN analyst ratings
or view top-rated stocks.

What is Regeneron Pharmaceuticals' stock price forecast for 2023?

20 equities research analysts have issued twelve-month price objectives for Regeneron Pharmaceuticals' shares. Their REGN share price forecasts range from $625.00 to $970.00. On average, they anticipate the company's share price to reach $786.15 in the next twelve months. This suggests a possible upside of 5.8% from the stock's current price.
View analysts price targets for REGN
or view top-rated stocks among Wall Street analysts.

How have REGN shares performed in 2023?

Regeneron Pharmaceuticals' stock was trading at $721.49 at the beginning of the year. Since then, REGN stock has increased by 3.0% and is now trading at $742.83.
View the best growth stocks for 2023 here
.

When is Regeneron Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 3rd 2023.
View our REGN earnings forecast
.

How can I listen to Regeneron Pharmaceuticals' earnings call?

Regeneron Pharmaceuticals will be holding an earnings conference call on Friday, February 3rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released its quarterly earnings results on Thursday, November, 3rd. The biopharmaceutical company reported $9.98 EPS for the quarter, topping analysts' consensus estimates of $8.55 by $1.43. The biopharmaceutical company had revenue of $2.94 billion for the quarter, compared to analysts' expectations of $2.79 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 31.16% and a net margin of 39.17%.

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include New York State Teachers Retirement System (0.11%), Assenagon Asset Management S.A. (0.11%), Pendal Group Ltd (0.11%), Natixis Advisors L.P. (0.10%), Ardevora Asset Management LLP (0.08%) and Bank Julius Baer & Co. Ltd Zurich (0.07%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends
.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $742.83.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $80.89 billion and generates $16.07 billion in revenue each year. The biopharmaceutical company earns $8.08 billion in net income (profit) each year or $47.43 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

The company employs 10,368 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113.

This page (NASDAQ:REGN) was last updated on 1/29/2023 by MarketBeat.com Staff